Regulatory approval

Published by the European Medicines Agency. Approved

The European Medicines Agency (EMA) has authorized alectinib as a monotherapy for the treatment of adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) previously treated with crizotinib.

This is written in the approval document as:

Alecensa as monotherapy is indicated for the treatment of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib.

Citation

Roche Registration GmbH. Alecensa (alectinib) [product information]. European Medicines Agency website. https://www.ema.europa.eu/en/documents/product-information/alecensa-epar-product-information_en.pdf. Revised June 2024. Accessed October 18, 2024.

Therapeutic response

Precision oncology relationships for therapeutic response derived from this regulatory approval.

Organizations	Biomarkers	Cancer types	Therapies
EMA (1)	v::ALK	Non-Small Cell Lung Cancer	Alectinib

Contributions

Date	Contributor	Description
2024-10-20	Van Allen lab	Adding EMA approvals for use to database
2017-02-16	European Medicines Agency	Indication received approval from the European Commission.